Heart Failure with Preserved Ejection Fraction (HFpEF) Overview
Learn About Heart Failure with Preserved Ejection Fraction (HFpEF)
Wake Forest University Health Sciences
Dalane Kitzman is a Cardiologist in Winston Salem, North Carolina. Dr. Kitzman is rated as an Elite provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Atherosclerosis, and Cardiomyopathy. Dr. Kitzman is currently accepting new patients.
Duke Health Integrated Practice Inc
Robert Mentz is a Cardiologist and an Advanced Heart Failure and Transplant Cardiologist in Durham, North Carolina. Dr. Mentz is rated as an Elite provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Low Blood Pressure, Heart Transplant, and Endoscopy. Dr. Mentz is currently accepting new patients.
University Medical Associates Of The Medical University Of South Carol
Sheldon Litwin is a Cardiologist and an Advanced Heart Failure and Transplant Cardiologist in Charleston, South Carolina. Dr. Litwin is rated as an Elite provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure, Cardiomyopathy, Gastric Bypass, and Cardiac Ablation. Dr. Litwin is currently accepting new patients.
Summary: This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Summary: The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is t...

